NasdaqGS - Delayed Quote USD

Beam Therapeutics Inc. (BEAM)

21.60 -1.14 (-5.01%)
At close: April 25 at 4:00 PM EDT
22.04 +0.44 (+2.04%)
Pre-Market: 8:42 AM EDT
All All Favorites Text Statistics Technicals Fibonacci Markings Lines
Loading Chart for BEAM

Recent News: BEAM

View More
Beam Therapeutics (NASDAQ:BEAM) Is In A Good Position To Deliver On Growth Plans

Beam Therapeutics (NASDAQ:BEAM) Is In A Good Position To Deliver On Growth Plans
Simply Wall St. 15 days ago
Why Is Beam Therapeutics (BEAM) Down 22.1% Since Last Earnings Report?

Why Is Beam Therapeutics (BEAM) Down 22.1% Since Last Earnings Report?
Zacks 28 days ago
Beam Therapeutics Announces Clearance of Clinical Trial Authorisation Application for BEAM-302 for the Treatment of Alpha-1 Antitrypsin Deficiency (AATD)

Beam Therapeutics Announces Clearance of Clinical Trial Authorisation Application for BEAM-302 for the Treatment of Alpha-1 Antitrypsin Deficiency (AATD)
GlobeNewswire last month
Beam Therapeutics Inc. (NASDAQ:BEAM) Analysts Are Cutting Their Estimates: Here's What You Need To Know

Beam Therapeutics Inc. (NASDAQ:BEAM) Analysts Are Cutting Their Estimates: Here's What You Need To Know
Simply Wall St. last month
News Flash: 11 Analysts Think Beam Therapeutics Inc. (NASDAQ:BEAM) Earnings Are Under Threat

News Flash: 11 Analysts Think Beam Therapeutics Inc. (NASDAQ:BEAM) Earnings Are Under Threat
Simply Wall St. last month
Beam Therapeutics to Participate in Upcoming March 2024 Investor Conferences

Beam Therapeutics to Participate in Upcoming March 2024 Investor Conferences
GlobeNewswire last month
Beam Therapeutics Full Year 2023 Earnings: Beats Expectations

Beam Therapeutics Full Year 2023 Earnings: Beats Expectations
Simply Wall St. last month
Beam Rockets 26%, Hitting A Year High, On Its Efforts To Take On Crispr's New Gene-Editing Drug

Beam Rockets 26%, Hitting A Year High, On Its Efforts To Take On Crispr's New Gene-Editing Drug
Investor's Business Daily last month
Beam Therapeutics Stock Jumps To Higher RS Level On Earnings Beat

Beam Therapeutics Stock Jumps To Higher RS Level On Earnings Beat
Investor's Business Daily last month
Beam Therapeutics Inc (BEAM) Reports Strong Year-End Financials with Key Clinical Milestones on ...

Beam Therapeutics Inc (BEAM) Reports Strong Year-End Financials with Key Clinical Milestones on ...
GuruFocus.com last month
Beam Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Reiterates Anticipated Milestones

Beam Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Reiterates Anticipated Milestones
GlobeNewswire last month
Recent uptick might appease Beam Therapeutics Inc. (NASDAQ:BEAM) institutional owners after losing 13% over the past year

Recent uptick might appease Beam Therapeutics Inc. (NASDAQ:BEAM) institutional owners after losing 13% over the past year
Simply Wall St. last month
View More

Related Tickers

NTLA Intellia Therapeutics, Inc.
20.02
-5.43%
 
VERV Verve Therapeutics, Inc.
6.22
-5.47%
 
PRME Prime Medicine, Inc.
4.3000
-8.51%
 
CRBU Caribou Biosciences, Inc.
3.7600
-2.34%
 
EDIT Editas Medicine, Inc.
5.22
-2.43%
 
CRSP CRISPR Therapeutics AG
53.73
-3.45%
 
SANA Sana Biotechnology, Inc.
8.50
-0.93%
 
RXRX Recursion Pharmaceuticals, Inc.
7.84
-1.26%
 
DNA Ginkgo Bioworks Holdings, Inc.
0.7777
-8.05%
 
FATE Fate Therapeutics, Inc.
3.8700
-10.00%